Ultragenyx's rare disease drug fails in late-stage trial; shares plunge

Ultragenyx Pharmaceutical said on ‌Wednesday its experimental drug for a rare genetic neurodevelopmental disorder did not ​meet the main goal in ​a late-stage trial, sending its shares ⁠down 40% in af...

本文内容来自外部来源，点击「继续访问」将跳转到原始发布站点。